1. Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study
- Author
-
Michele Malagola, MD, Nicola Polverelli, MD, Massimo Martino, MD, Francesca Patriarca, MD, Benedetto Bruno, MD, Luisa Giaccone, MD, Giovanni Grillo, MD, Stefania Bramanti, MD, Paolo Bernasconi, MD, Marco De Gobbi, MD, Annalisa Natale, MD, Elisabetta Terruzzi, MD, Attilio Olivieri, MD, Patrizia Chiusolo, MD, Angelo Michele Carella, MD, Marco Casini, MD, Enrico Maffini, MD, Chiara Nozzoli, MD, Patrizio Mazza, MD, Simona Bassi, Francesco Onida, MD, Adriana Vacca, MD, Sadia Falcioni, MD, Mario Luppi, MD, Anna Paola Iori, MD, Vincenzo Pavone, MD, Cristina Skert, MD, Paola Carluccio, MD, Carlo Borghero, MD, Anna Proia, MD, Carmine Selleri, MD, Vicky Rubini, MD, Nicoletta Sacchi, MD, Elena Oldani, MD, Francesca Bonifazi, MD, Fabio Ciceri, MD, Domenico Russo, MD, Simona Bernardi, Mirko Farina, Maria Fiore, Maria Teresa Lupo Stanghellini, Renato Fanin, Danilo Giuseppe Faraci, Luca Castagna, Anna Amelia Colombo, Paolo Nicoli, Stella Santarone, Ilaria Scortechini, Elisabetta Metafuni, Emanuela Merla, Irene Cavattoni, Ilaria Cutini, Annamaria Mazzone, Giorgia Saporiti, Filippo Antonio Canale, Eugenia Piras, Piero Galieni, Giulia Debbia, Ursula La Rocca, Anna Mele, Francesca Carobolante, Francesca Elice, and Fulvia Fanelli
- Subjects
Surgery ,RD1-811 - Abstract
Background. The conditioning regimens with different alkylators at different doses can influence the outcome of allogeneic stem cell transplantation (SCT), but conclusive data are missing. Methods. With the aim to analyze real-life allogeneic SCTs performed in Italy between 2006 and 2017 in elderly patients (aged >60 y) with acute myeloid leukemia or myelodysplastic syndrome, we collected 780 first transplants data. For analysis purposes, patients were grouped according to the type of alkylator included in the conditioning (busulfan [BU]-based; n = 618; 79%; treosulfan [TREO]-based; n=162; 21%). Results. No significant differences were observed in nonrelapse mortality, cumulative incidence of relapse, and overall survival, although in the TREO-based group, we observed a greater proportion of elderly patients (P
- Published
- 2023
- Full Text
- View/download PDF